Abstract
Fas-mediated apoptosis is essential for the elimination of cells, and impaired apoptosis can have severe detrimental consequences. Bisindolylmaleimide VIII potentiated Fas-mediated apoptosis in human astrocytoma 1321N1 cells and in Molt-4 T cells, both of which were devoid of apoptosis induced by anti-Fas antibody in the absence of bisindolylmaleimide VIII, and in Jurkat and CEM-6 T cells, which showed slight and moderate apoptotic responses, respectively, to low levels of Fas stimulation. Potentiation of Fas-mediated apoptosis by bisindolylmaleimide VIII was selective for activated, rather than non-activated, T cells, and was Fas-dependent, as it was not observed in T cells from Fas-deficient lpr/lpr mice. Administration of bisindolylmaleimide VIII to rats during autoantigen stimulation prevented the development of symptoms of T cell-mediated autoimmune diseases in two models, the Lewis rat model of experimental allergic encephalitis and the Lewis adjuvant arthritis model. Thus, the use of agents such as bisindolylmaleimide VIII may be therapeutically useful for supporting more effective elimination of detrimental cells through enhancement of Fas-dependent apoptosis signaling.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jacobson, M.D., Weil, M. & Raff, M.C. Programmed cell death in animal development. Cell 88, 347–354 ( 1997).
Itoh, N. et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233– 243 (1991).
Yonehara, S., Ishii, A. & Yonehara, M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 169, 1747– 1756 (1989).
Suda, T., Takahashi, T., Gostein, P. & Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169 –1178 (1993).
Nagata, S. Apoptosis by death factor. Cell 88, 355– 365 (1997).
Saas, P. et al. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? J. Clin. Invest. 99, 1173–1178 (1997).
Weller, M. et al. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. J. Clin. Invest. 94, 954– 964 (1994).
Watanabe-Fukunaga, R. et al. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314–317 (1992).
Takahashi, T. et al. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 76, 969–976 (1994).
Ju, S.T. et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 373, 444 –448 (1995).
Brunner, T. et al. Cell-autonomous Fas(CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373, 441–444 (1995).
Dhein, J., Walczak, H., Baumler, C., Debatin, K.M. & Krammer, P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438–441 (1995).
Su, X. et al. Defective expression of hematopoietic protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 2, 353–362 ( 1995).
Miyawaki, T. et al. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol. 149, 3753–3758 ( 1992).
Ehl, S. et al. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J. Immunol. 156, 2357–2360 (1996).
Toullec, D. et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266, 1571–1581 (1991).
Bit, R.A. et al. Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. J. Med. Chem. 36, 21–29 ( 1993).
Jacobson, P.B. et al. Anti-inflammatory properties of Go 6850: a selective inhibitor of protein kinase C. J. Pharmacol. Exp. Therap. 275 , 995–1002 (1995).
Suen, W.E., Bergman, C.M., Hjelmstrom, P. & Ruddle, N.H. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J. Exp. Med. 186, 1233– 1240 (1997).
Beltman, J., McCormick, F. & Cook, S.J. The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase. J. Biol. Chem. 271, 27018–27024 (1996).
Alessi, D.R. The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1β (Rsk-2) and p70 S6 kinase. FEBS Lett. 402, 121–123 (1997).
Yeo, E-J., Provost, J.J. & Exton, J.H. Dissociation of tyrosine phosphorylation and activation of phosphoinositide phospholipase C induced by the protein kinase C inhibitor Ro-31-8220 in Swiss 3T3 cells treated with platelet-derived growth factor. Biochim. Biophys. Acta 1356, 308– 320 (1997).
McFarland, H.I. et al. Amelioration of autoimmune reactions by antigen-induced apoptosis of T cells. Adv. Exp. Med. Biol. 383, 157 –166 (1995).
Tabi, Z., McCombe, P.A. & Pender, M.P. Antigen-specific down-regulation of myelin basic protein-reactive T cells during spontaneous recovery from experimental autoimmune encephalomyelitis: further evidence of apoptotic deletion of autoreactive T cells in the central nervous system. Int. Immunol. 7, 967– 973 (1995).
Sun, D., Qin, Y., Chluba, J., Epplen, J.T. & Wekerle, H. . Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T cell interactions. Nature 332, 843–845 (1988).
Acknowledgements
We thank W.J. Koopman and R.P. Kimberly for their critical comments and F. Hunter for editing the manuscript. T.Z. is supported by the Arthritis Foundation, the Juvenile Diabetes Foundation, a grant from the NIH (AR44982), and a grant from Sankyo (Japan). R.S.J. is supported by grants from the NIH (MH38752 and AG06569).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zhou, T., Song, L., Yang, P. et al. Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nat Med 5, 42–48 (1999). https://doi.org/10.1038/4723
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/4723
This article is cited by
-
A cell-based drug delivery platform for treating central nervous system inflammation
Journal of Molecular Medicine (2021)
-
Insulin directly stimulates mitochondrial glucose oxidation in the heart
Cardiovascular Diabetology (2020)
-
p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes
Oncogene (2018)
-
Specific elimination of effector memory CD4+ T cells due to enhanced Fas signaling complex formation and association with lipid raft microdomains
Cell Death & Differentiation (2011)
-
Cutaneous Anaplastic Large Cell Lymphoma and Peripheral T-Cell Lymphoma NOS Show Distinct Chromosomal Alterations and Differential Expression of Chemokine Receptors and Apoptosis Regulators
Journal of Investigative Dermatology (2010)